Literature DB >> 21472115

Occult hepatitis B virus infection: a complex entity with relevant clinical implications.

Juan-Ramon Larrubia.   

Abstract

Occult hepatitis B virus (HBV) infection is a world-wide entity, following the geographical distribution of detectable hepatitis B. This entity is defined as the persistence of viral genomes in the liver tissue and in some instances also in the serum, associated to negative HBV surface antigen serology. The molecular basis of the occult infection is related to the life cycle of HBV, which produces a covalently closed circular DNA that persists in the cell nuclei as an episome, and serves as a template for gene transcription. The mechanism responsible for the HBsAg negative status in occult HBV carriers is a strong suppression of viral replication, probably due to the host's immune response, co-infection with other infectious agents and epigenetic factors. There is emerging evidence of the potential clinical relevance of occult HBV infection, since this could be involved in occult HBV transmission through orthotopic liver transplant and blood transfusion, reactivation of HBV infection during immunosuppression, impairing chronic liver disease outcome and acting as a risk factor for hepatocellular carcinoma. Therefore it is important to bear in mind this entity in cryptogenetic liver diseases, hepatitis C virus/HIV infected patients and immunosupressed individuals. It is also necessary to increase our knowledge in this fascinating field to define better strategies to diagnose and treat this infection.

Entities:  

Keywords:  Hepatitis B virus; Occult infection; Persistent infection

Mesh:

Substances:

Year:  2011        PMID: 21472115      PMCID: PMC3070120          DOI: 10.3748/wjg.v17.i12.1529

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin.

Authors:  Marion Levast; Sylvie Larrat; Marie-Ange Thelu; Sandrine Nicod; Agnès Plages; Alice Cheveau; Jean-Pierre Zarski; Jean-Marie Seigneurin; Patrice Morand; Vincent Leroy
Journal:  J Med Virol       Date:  2010-05       Impact factor: 2.327

2.  Statements from the Taormina expert meeting on occult hepatitis B virus infection.

Authors:  Giovanni Raimondo; Jean-Pierre Allain; Maurizia R Brunetto; Marie-Annick Buendia; Ding-Shinn Chen; Massimo Colombo; Antonio Craxì; Francesco Donato; Carlo Ferrari; Giovanni B Gaeta; Wolfram H Gerlich; Massimo Levrero; Stephen Locarnini; Thomas Michalak; Mario U Mondelli; Jean-Michel Pawlotsky; Teresa Pollicino; Daniele Prati; Massimo Puoti; Didier Samuel; Daniel Shouval; Antonina Smedile; Giovanni Squadrito; Christian Trépo; Erica Villa; Hans Will; Alessandro R Zanetti; Fabien Zoulim
Journal:  J Hepatol       Date:  2008-07-31       Impact factor: 25.083

3.  Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients.

Authors:  Ozcan Ceneli; Zübeyde Nur Ozkurt; Kadir Acar; Seyyal Rota; Sahika Zeynep Aki; Zeynep-Arzu Yeğin; Münci Yağci; Seren Ozenirler; Gülsan Türköz Sucak
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

4.  The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients.

Authors:  Norah J Shire; Susan D Rouster; Sandra D Stanford; Jason T Blackard; Christina M Martin; Carl J Fichtenbaum; Kenneth E Sherman
Journal:  J Acquir Immune Defic Syndr       Date:  2007-03-01       Impact factor: 3.731

Review 5.  Management of occult hepatitis B virus infection: an update for the clinician.

Authors:  José Luis Lledó; Conrado Fernández; María Luisa Gutiérrez; Sara Ocaña
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

Review 6.  Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections.

Authors:  Maria Stella De Mitri; Romina Cassini; Mauro Bernardi
Journal:  Eur J Cancer       Date:  2010-04-21       Impact factor: 9.162

7.  Development of a new ultra sensitive real-time PCR assay (ultra sensitive RTQ-PCR) for the quantification of HBV-DNA.

Authors:  Dimitrios Paraskevis; Apostolos Beloukas; Catherine Haida; Antigoni Katsoulidou; Zisis Moschidis; Helen Hatzitheodorou; Agoritsa Varaklioti; Vana Sypsa; Angelos Hatzakis
Journal:  Virol J       Date:  2010-03-12       Impact factor: 4.099

Review 8.  Control of cccDNA function in hepatitis B virus infection.

Authors:  Massimo Levrero; Teresa Pollicino; Jorg Petersen; Laura Belloni; Giovanni Raimondo; Maura Dandri
Journal:  J Hepatol       Date:  2009-06-10       Impact factor: 25.083

Review 9.  Transfusion-transmitted hepatitis B virus infection.

Authors:  Daniel Candotti; Jean-Pierre Allain
Journal:  J Hepatol       Date:  2009-06-10       Impact factor: 25.083

10.  Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China.

Authors:  Yong Fang; Qing-Long Shang; Jian-Yu Liu; Di Li; Wei-Zhen Xu; Xu Teng; Hong-Wei Zhao; Li-Juan Fu; Feng-Min Zhang; Hong-Xi Gu
Journal:  J Infect       Date:  2009-03-29       Impact factor: 6.072

View more
  11 in total

Review 1.  Hepatitis B virus management to prevent reactivation after chemotherapy: a review.

Authors:  Jessica P Hwang; John M Vierling; Andrew D Zelenetz; Susan C Lackey; Rohit Loomba
Journal:  Support Care Cancer       Date:  2012-08-30       Impact factor: 3.603

Review 2.  Prevention of hepatitis B virus infection: from the past to the future.

Authors:  R Orlando; M Foggia; A E Maraolo; S Mascolo; G Palmiero; O Tambaro; G Tosone
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-13       Impact factor: 3.267

Review 3.  Occult hepatitis B virus and hepatocellular carcinoma.

Authors:  Teresa Pollicino; Carlo Saitta
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 4.  Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations.

Authors:  Fernando Bessone; Melisa Dirchwolf
Journal:  World J Hepatol       Date:  2016-03-18

5.  Unusual presentation of hepatitis B serological markers in an Amerindian community of Venezuela with a majority of occult cases.

Authors:  Nathalia E Cardona; Carmen L Loureiro; Domingo J Garzaro; María C Duarte; Daisy M García; Milian C Pacheco; Isabelle Chemin; Flor H Pujol
Journal:  Virol J       Date:  2011-12-09       Impact factor: 4.099

Review 6.  Occult HBV infection: a faceless enemy in liver cancer development.

Authors:  Jaime Morales-Romero; Gustavo Vargas; Rebeca García-Román
Journal:  Viruses       Date:  2014-04-08       Impact factor: 5.048

7.  Occult Hepatitis B virus infection in previously screened, blood donors in Ile-Ife, Nigeria: implications for blood transfusion and stem cell transplantation.

Authors:  Amadin A Olotu; Adesola O Oyelese; Lateef Salawu; Rosemary A Audu; Azuka P Okwuraiwe; Aaron O Aboderin
Journal:  Virol J       Date:  2016-05-05       Impact factor: 4.099

8.  Prevalence of Serologic Hepatitis B Markers in Blood Donors From Puebla, Mexico: The Association of Relatively High Levels of Anti-Core Antibodies With the Detection of Surface Antigen and Genomic DNA.

Authors:  Francisca Sosa-Jurado; Nora Hilda Rosas-Murrieta; Belinda Guzman-Flores; Cintia Perez Zempoaltecalt; Ana Patricia Sanchez Torres; Leticia Ramirez Rosete; Maribel Bernal-Soto; Luis Marquez-Dominguez; Daniel Melendez-Mena; Miguel Angel Mendoza Torres; Maria Teresa Lopez Delgado; Julio Reyes-Leyva; Veronica Vallejo-Ruiz; Gerardo Santos-Lopez
Journal:  Hepat Mon       Date:  2016-06-01       Impact factor: 0.660

9.  Occult hepatitis B: clinical viewpoint and management.

Authors:  Mehdi Zobeiri
Journal:  Hepat Res Treat       Date:  2013-03-04

10.  Detection of occult hepatitis B in serum and oral fluid samples.

Authors:  Moyra Machado Portilho; Leticia Cancella Nabuco; Cristiane Alves Villela-Nogueira; Carlos Eduardo Brandão-Mello; José Henrique Pilotto; Geane Lopes Flores; Lia Laura Lewis-Ximenez; Elisabeth Lampe; Livia Melo Villar
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-01       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.